Search results
Results from the WOW.Com Content Network
NovoBiotic Pharmaceuticals owns the patent rights [3] to teixobactin, an antibiotic that has been shown to be active against pathogenic Gram-positive bacteria that have developed resistance to available approved antibiotics. The discovery and characterization of the compound was reported in 2015 in a collaboration between NovoBiotic ...
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
As of 2019, twelve of top 20 biopharmaceutical companies in the world has U.S. headquarters in the state. [9] [10] Below is a list of notable New York metropolitan area biotechnology and pharmaceutical corporations, including companies with either global or U.S. headquarters in the metropolitan region encompassing and surrounding New York City.
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
For premium support please call: 800-290-4726 more ways to reach us
In combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant ...
The U.S. Food and Drug Administration on Thursday sent letters to nine companies including e-commerce retailer Chewy warning them against selling the products that it said contained antibiotics ...
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, [1] and in the United States, as Relyvrio, in September 2022. [2]